Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sanofi, Amgen...

    Sanofi, Amgen Cholesterol Drugs win UK Backing After Price Cuts

    Written by savita thakur thakur Published On 2016-05-06T13:27:17+05:30  |  Updated On 6 May 2016 1:27 PM IST
    Sanofi, Amgen Cholesterol Drugs win UK Backing After Price Cuts

    London : Two rival cholesterol-lowering injections from Sanofi and Amgen have been recommended by Britain's healthcare cost watchdog after the manufacturers offered special discounts to the country's state-run health service.


    Sanofi's Praluent, which was developed with Regeneron , and Amgen's Repatha are both so called PCSK9 medicines that work in a different way to existing cholesterol fighters such as statins.


    The National Institute for Health and Care Excellence (NICE) said in draft guidance on Friday that both drugs could be considered for use by people whose cholesterol is still not under control despite trying other treatments.


    It stressed that the medicines would only be cost-effective with the promised discounts.


    Both drugs cost more than 4,000 pounds ($5,780) per patient a year in Britain. That is already a lot less than their U.S. list price of around $14,000, but Sanofi and Amgen have committed to discount the British price by a further undisclosed amount for the UK National Health Service.


    While Praluent and Repatha are both viewed by analysts as eventual multi-billion-dollar-a-year sellers, demand for the medicines in markets worldwide so far has proved disappointing. ($1 = 0.6921 pounds) (Reporting by Ben Hirschler; editing by Adrian Croft)

    Adrian CroftAmgenBen Hirschlercholesterol drugNational Institute for Health and Care ExcellenceNICEPCSK9RegeneronSanofi
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok